Question

A 63-year-old woman with type 2 diabetes, albuminuric chronic kidney disease (eGFR 55 mL/min/1.73 m², albumin-to-creatinine ratio 15 mg/mmol) and hypertension is on metformin and perindopril. Her HbA1c is 60 mmol/mol despite adherence. Which additional glucose-lowering agent is preferred because of renal and cardiovascular benefits?

Accepted Answer

SGLT2 inhibitor (e.g. empagliflozin)

Answer

Dipeptidyl peptidase-4 inhibitor (e.g. sitagliptin)

Answer

Sulfonylurea (e.g. gliclazide modified release)

Answer

Thiazolidinedione (e.g. pioglitazone)

Answer

Alpha-glucosidase inhibitor (e.g. acarbose)

Practice question